Overview
- Editors:
-
-
Stephen H. Tsang
-
Edward S. Harkness Eye Institute, Department of Ophthalmology, Columbia University, New York, USA
- Describes a wide range of possible applications, from oculofacial plastic surgery to the restoration of sight lost by degenerative disorders and glaucoma, to cancer research
- Gives a comprehensive account of types of safety trials that may be used to assess stem cell-based treatments’ viability
- Contains a discussion of the evidence that cancer stem cells can lead to uveal melanoma
- Includes supplementary material: sn.pub/extras
Access this book
Other ways to access
Table of contents (11 chapters)
-
-
- Mark A. Fields, John Hwang, Jie Gong, Hui Cai, Lucian V. Del Priore
Pages 1-29
-
- Bryan J. Winn, Mary Whitman
Pages 31-41
-
- Roy S. Chuck, Alexandra A. Herzlich, Philip Niles
Pages 43-56
-
- Ales Cvekl, Ying Yang, Yang Jing, Qing Xie
Pages 57-73
-
- Jonathan Hertz, Jeffrey L. Goldberg
Pages 75-97
-
-
- Xining He, Deniz Erol, Stephen H. Tsang
Pages 107-120
-
-
- Helen Kalirai, Bertil E. Damato, Sarah E. Coupland
Pages 139-151
-
- Chen-Hsien Su, Deniz Erol
Pages 153-170
-
- Rony Gelman, Stephen H. Tsang
Pages 171-178
-
Back Matter
Pages 179-186
About this book
Patient specific and disease specific stem cell lines have already introduced groundbreaking advances into the research and practice of ophthalmology. This volume provides a comprehensive and engaging overview of the latest innovations in the field. Twelve chapters discuss the fastest growing areas in ophthalmological stem cell research, from disease modelling, drug screening and gene targeting to clinical genetics and regenerative treatments. Innovative results from stem cell research of the past decade are pointing the way toward practicable treatments for retinitis pigmentosa, age related macular degeneration, and Stargardt disease. What future directions will stem cell research take? Researchers, graduate students, and fellows alike will find food for thought in this insightful guide tapping into the collective knowledge of leaders in the field. Stem Cells in Ophthalmology is part of the Stem Cells in Regenerative Medicine series dedicated to discussing current challenges and future directions in stem cell research.
Editors and Affiliations
-
Edward S. Harkness Eye Institute, Department of Ophthalmology, Columbia University, New York, USA
Stephen H. Tsang
About the editor
Stephen Tsang, MD, Ph.D. is an associate professor of Ophthalmology, Pathology and Cell Biology. Since 1992, he has been working on gene-targeting in stem cells and created the first gene-targeted model for a recessive form of retinitis pigmentosa with gene-targeting in embryonic stem cell technology; this model is used in current research by numerous laboratories. He received his M.D.-Ph.D. degrees from the NIH-National Institute of General Medical Sciences Medical Scientist Training Program (MSTP) at Columbia University. Dr. Tsang then completed his residency at Jules Stein Eye Institute/UCLA. Dr. Tsang's contributions to retinal degeneration research are known internationally and he is a member of the Fight-For-Sight grant-in-aid review panel for the last eight years. In his New York State supported stem cell program (N09G-302), we are examining embryonic stem (ES) cells to model and replace diseased human retinal cells. His skills are being recognized by the 2005 Bernard Becker-“Association of University Professor in Ophthalmology”-“Research to Prevent Blindness” Award. Dr. Tsang also participates in resident teaching and is the Columbia ophthalmology basic science course director. He is a member of the Macular Society. Named one of America’s Top Ophthalmologists in 2009, he has published over 60 research articles and lectured internationally on personalized medicine and stem cells in regenerative medicine.
